128 related articles for article (PubMed ID: 21174607)
1. Transplantable delivery systems for in situ controlled release of bisphosphonate in orthopedic therapy.
Su K; Shi X; Varshney RR; Wang DA
Expert Opin Drug Deliv; 2011 Jan; 8(1):113-26. PubMed ID: 21174607
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates: therapeutics potential and recent advances in drug delivery.
Fazil M; Baboota S; Sahni JK; Ameeduzzafar ; Ali J
Drug Deliv; 2015 Jan; 22(1):1-9. PubMed ID: 24404750
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
Cosman F; Borges JL; Curiel MD
Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
[TBL] [Abstract][Full Text] [Related]
4. [Bisphosphonate].
Hagino H
Nihon Rinsho; 2015 Oct; 73(10):1683-9. PubMed ID: 26529930
[TBL] [Abstract][Full Text] [Related]
5. [Bisphosphonate treatment of osteoporosis and other skeletal diseases].
Syversen U; Halse JI
Tidsskr Nor Laegeforen; 2011 Feb; 131(3):244-7. PubMed ID: 21304573
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates: focus on inflammation and bone loss.
Iannitti T; Rosini S; Lodi D; Frediani B; Rottigni V; Palmieri B
Am J Ther; 2012 May; 19(3):228-46. PubMed ID: 22549638
[TBL] [Abstract][Full Text] [Related]
7. [The successful development of bisphosphonates in the therapy of osteoporosis].
Fassbender WJ; Stumpf UC; Kurth A
Med Klin (Munich); 2006 Jun; 101 Suppl 1():6-14. PubMed ID: 16826363
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
Grewal VS; Fayans EP
Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
[TBL] [Abstract][Full Text] [Related]
9. [Developments in research of local bisphosphonate delivery system of implant denture].
Zang C; Zhai J; Meng Y; Liang X
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2011 Apr; 28(2):415-8. PubMed ID: 21604513
[TBL] [Abstract][Full Text] [Related]
10. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem.
Cramer JA; Silverman S
Am J Med; 2006 Apr; 119(4 Suppl 1):S12-7. PubMed ID: 16563936
[TBL] [Abstract][Full Text] [Related]
11. [Bisphosphonate therapy for osteoporosis and bone strength].
Kishimoto H
Clin Calcium; 2006 Sep; 16(9):1513-19. PubMed ID: 16951477
[TBL] [Abstract][Full Text] [Related]
12. [New development in bisphosphonate treatment. Clinical significance of combinatorial therapies with bisphosphonates and parathyroid hormone for osteoporosis].
Takeuchi Y
Clin Calcium; 2009 Jan; 19(1):85-90. PubMed ID: 19122268
[TBL] [Abstract][Full Text] [Related]
13. Identification of dynamin-2-mediated endocytosis as a new target of osteoporosis drugs, bisphosphonates.
Masaike Y; Takagi T; Hirota M; Yamada J; Ishihara S; Yung TM; Inoue T; Sawa C; Sagara H; Sakamoto S; Kabe Y; Takahashi Y; Yamaguchi Y; Handa H
Mol Pharmacol; 2010 Feb; 77(2):262-9. PubMed ID: 19903825
[TBL] [Abstract][Full Text] [Related]
14. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
Emkey RD; Ettinger M
Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
[TBL] [Abstract][Full Text] [Related]
15. Delivery of parathyroid hormone for the treatment of osteoporosis.
Morley P
Expert Opin Drug Deliv; 2005 Nov; 2(6):993-1002. PubMed ID: 16296804
[TBL] [Abstract][Full Text] [Related]
16. Drug insight: the use of bisphosphonates for the prevention and treatment of osteoporosis in men.
Brown SA; Guise TA
Nat Clin Pract Urol; 2007 Jun; 4(6):310-20. PubMed ID: 17551535
[TBL] [Abstract][Full Text] [Related]
17. Nitrogen-containing bisphosphonate mechanism of action.
Reszka AA; Rodan GA
Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
[TBL] [Abstract][Full Text] [Related]
18. In vivo bone augmentation in an osteoporotic environment using bisphosphonate-loaded calcium deficient apatite.
Verron E; Gauthier O; Janvier P; Pilet P; Lesoeur J; Bujoli B; Guicheux J; Bouler JM
Biomaterials; 2010 Oct; 31(30):7776-84. PubMed ID: 20643480
[TBL] [Abstract][Full Text] [Related]
19. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
20. Survey of bisphosphonate regimen preferences in an urban community health center.
Ryzner KL; Burkiewicz JS; Griffin BL; Komperda KE
Consult Pharm; 2010 Oct; 25(10):671-5. PubMed ID: 21030357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
